Litcius/Paper detail

Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)

Melhem Solh, Scott R. Solomon, Lawrence E. Morris, Xu Zhang, H. Kent Holland, Asad Bashey

2020Leukemia Research12 citationsDOI

Topics & Concepts

Flag (linear algebra)IdarubicinCytarabineMedicineInternal medicineRegimenGastroenterologyFludarabineAnthracyclineRefractory (planetary science)SurgeryLeukemiaChemotherapyCancerCyclophosphamideBreast cancerAlgebra over a fieldPhysicsPure mathematicsAstrobiologyMathematicsAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments
Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine) | Litcius